Enrolling by invitationNo phase
Long-term safety follow-up of patients treated with WU-CART-007 cell therapy
Follows people treated with WU-CART-007 cells for T-cell leukemia or lymphoma for years.
Plain-language title generated from the registry record
Registry title: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Key facts
- Where
- Melbourne, AustraliaSee the site
Where in Australia
- Peter MacCullam Cancer CenterMelbourne, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Allotera Therapeutics
- Trial code
- NCT05509855
- Record updated
- 20 November 2024
- Original description
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.Read full original descriptionShow less
A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.